Literature DB >> 18609262

Good response to IL-1beta blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies.

C M Hedrich1, B Fiebig, S Sallmann, N Bruck, G Hahn, J Roesler, A Roesen-Wolff, G Heubner, M Gahr.   

Abstract

Chronic infantile neurological cutaneous and articular (CINCA) syndrome is an autoinflammatory disease, defined by the triad of urticarial rash, neurological manifestations, and arthropathy, accompanied by recurrent fevers and systemic inflammation. Increasing neurological deficits result from aseptic meningitis. Sensorineural hearing loss and progressive loss of vision caused by keratoconjunctivitis or papilloedema may emerge. An autosomal-dominant inheritance is suspected although sporadic cases are reported frequently. Sixty per cent of CINCA patients carry mutations in the cold-induced autoinflammatory syndrome (CIAS1) gene. We report the favourable response of a 23-year-old CINCA patient without CIAS1 mutations to treatment with the recombinant interleukin-1 (IL-1) receptor antagonist anakinra.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18609262     DOI: 10.1080/03009740801978889

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  8 in total

1.  Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity.

Authors:  Joshua N Finger; John D Lich; Lauren C Dare; Michael N Cook; Kristin K Brown; Chaya Duraiswami; John Bertin; John J Bertin; Peter J Gough
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

2.  "Mutation negative" familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies.

Authors:  C M Hedrich; N Bruck; D Paul; G Hahn; M Gahr; A Rösen-Wolff
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

3.  Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).

Authors:  C M Hedrich; N Bruck; B Fiebig; M Gahr
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

4.  Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA).

Authors:  Donato Rigante; Antonio Leone; Raffaella Marrocco; Maria Elena Laino; Achille Stabile
Journal:  Rheumatol Int       Date:  2011-01-15       Impact factor: 2.631

Review 5.  [Caspase-1 regulates autoinflammation in rheumatic diseases].

Authors:  S Winkler; C M Hedrich; A Rösen-Wolff
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

Review 6.  Primary immunodeficiency diseases associated with neurologic manifestations.

Authors:  Soodabeh Fazeli Dehkordy; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2011-10-26       Impact factor: 8.542

Review 7.  Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options.

Authors:  Christian Michael Hedrich; Hildegard Zappel; Simon Straub; Martin W Laass; Kathrin Wieczorek; Gabriele Hahn; Georg Heubner; Manfred Gahr
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 3.650

Review 8.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.